1 / 28

Antithrombotic management in the setting of Intracerebral Hemorrhage

Antithrombotic management in the setting of Intracerebral Hemorrhage. Girish Hiremath , MD, FAANS. Introduction. Spontaneous ICH ( sICH ) 15% of all acute strokes Deadliest stroke subtype 1 month mortality of 40% At 1 year, 75% die or are severely disabled

david-riggs
Télécharger la présentation

Antithrombotic management in the setting of Intracerebral Hemorrhage

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Antithrombotic management in the setting of Intracerebral Hemorrhage GirishHiremath, MD, FAANS

  2. Introduction • Spontaneous ICH (sICH) • 15% of all acute strokes • Deadliest stroke subtype • 1 month mortality of 40% • At 1 year, 75% die or are severely disabled • Initial hematoma volume remains strongest predictor of 30-day mortality and functional outcome • Only modifiable predictor of outcome Qureshi, Lancet 2009 Van Asch, Lancet Neurol 2010 Broderick, Stroke 1993

  3. Hematoma Volume • Larger more likely to expand • Early presentation after symptom onset • Anticoagulation use • Presence of APOE ε2 allele • CTA spot sign • Newer marker for hematoma expansion • Poor functional outcome, death • Low sensitivity Cucchiara, Stroke 2008 Broderick, Stroke 2007 Delgado, Stroke 2010 Brouwers, Stroke 2012

  4. Should patients be anticoagulated after a history of ICH? • Dilemma: pt with past ICH develops clear indication for A/C such as Afib • Risk of thromboembolism is 4.5% with Afib • Efficacy of warfarin for stroke prevention: 68% • Decision analysis models (no RCT’s) • Assumptions: • Relative risk of bleeding on ASA in this cohort—SDH = 2.0 • Relative risk of bleeding on A/C—ICH = 2.0; SDH = 4.0 • For 1000 patients with lobar ICH, A/C would result in 31 fewer thromboembolic events, but 150 additional ICH’s • Conclusions: • A/C not indicated after lobar ICH • A/C resumption unclear after deep ICH (probably no unless very high risk of ischemic stroke) • ASA indicated only if RR for deep ICH is < 1.3 and for lobar ICH < 1.04 Eckman, Stroke 2003

  5. If no anticoagulation, is antiplatelet better than no treatment at all?

  6. Case Example • 72 year old white man presents with expressive aphasia, headache, declining mental status • Likely spontaneous—no specific hx of trauma • On ASA/PLAVIX for CAD • L Acute SDH (2cm) with 1cm MLS; L inferior frontal contusion/ICH • Underwent platelet tx, emergent craniotomy, evacuation of SDH

  7. POD #1

  8. POD 2—more lethargic, worse expressive aphasia (cont’d plttx); CT shows recurrent L frontal ICH, SDH, MLS Redo Urgent Craniotomy…

  9. POD 4: doing well clinically, but draining scalp incision

  10. 3 wks later—wound infection/infected bone flap—wound washout, craniectomy

  11. ASA stopped (10 days prior), underwent Cranioplasty 5 months later with postop EDH (developed 12h after surgery with presentation of weak RUE, expressive aphasia)--underwent take back for evacuation

  12. Eventually did well—sutures out… (5 surgeries later)

  13. Story doesn’t end… • 1 week later: • Admitted to OSH with massive MI, resulting in resumption of ASA/PLAVIX…

  14. Antiplatelet use and ICH • 22071 male physicians (aged 40-84) randomly assigned to 325mg ASA or placebo qOD • At 5 yrs: • ASA use was associated with 2.14 X higher risk of hemorrhagic stroke • Swedish Aspirin Low-dose Trial (SALT) • 1360 pts with hx of TIA/minor stroke randomly assigned to 75mg/d of ASA or placebo for 2.8 yrs • ASA use associated with 2.78 X higher risk of hemorrhagic stroke Steering Committee of the Physicians’ Health Study Research Group; NEJM 1989 SALT Collaborative Group; Lancet 1991

  15. Antiplatelet use and ICH… • Meta-analysis of 16 RCT’s on ASA use • International study of 55462 participants • RR reduction of MI with ASA • RR reduction of ischemic stroke with ASA • RR increase in hemorrhagic stroke with ASA (84% increased RR) • (all three were significant at P <.001) He et al, JAMA 1998

  16. What about Recurrent ICH? • Meta-analysis of 1880 ICH survivors between 1982 and 2000 • Mean age 65 • Mean f/u: 3.4 yrs from index ICH • Stroke recurrence: • 59% hemorrhagic • 26% ischemic • Recurrent ICH occurs at 2X the rate of ischemic stroke in survivors of primary ICH • 2.4% per year rate of recurrent ICH • Higher risk with lobar hemorrhage Bailey et al; Neurology 2001

  17. Resumption of AP following ICH?Viswanathan et al • 207 patients with index ICH • Lobar • Deep • AP prescribed in 22% of survivors • Avg of 5.4 months after index ICH • Most commonly for ischemic cardiovascular dz • ICH recurred in 22% of survivors • No increase in risk of recurrent ICH with ASA resumption • (p = 0.73) • ICH location not factor (lobar vs. deep) • Limitations: • Selection bias (pts felt to be high risk for repeated ICH likely did not have AP resumption) • Resumption of ASAdid NOT significantly improve cardiovasc morbidity (p =.75) • Small sample size (only 46 pts had recurrent ICH) Viswanathan et al; Neurology 2006 Donnan and Ly; Neurology 2006

  18. Resumption of AP following ICHFlynn et al • Observational, Community-based study in Scotland • 417 pts with ICH • 120 prescribed Antiplatelet medications (28.8%) • Median time from d/c to AP use was 14.8 months • 40 ischemic strokes/MI • 14 recurrent ICH • Study found no association between AP use and recurrent ICH • Limitations: • Small sample size • Selection bias • ? Delay in resuming of AP to 14.8 months after index ICH Flynn et al; Stroke 2010

  19. In summary: When to resume ASA after ICH? • There is no good answer! • No good literature to guide the neurosurgeon (or neurologist) • There is not likely to be a RCT • In general, it is prudent to wait at least one month • Must be made on a case-by-case basis • NOT by a “protocol-driven” approach

  20. DVT Prophylaxis in the setting of ICH VTE is frequent in pts with ischemic and hemorrhagic stroke 5% of early deaths following stroke attributed to PE

  21. VTE in elective NS patients • Incidence of DVT in untreated NS pts: 18-50% • Multiple studies have shown the safety of pharmacological DVT prophylaxis in the setting of elective NS • In 555 pts undergoing elective NS procedures, LDSQUFH: • Reduced DVT by 43% (measured by U/S) • Risk reduction NOT assoc with incr hemorrhage • Did not alter the rate of PE • No correlation between DVT and PE • (In general, 30% of pts with acute PE have no LE DVT) • PE directly related only to length of procedure • (? Lack of statistical power) Khaldi et al; J Neurosurg 2011; Agnelli et al; NEJM 1998; Geerts; Chest 2001 Cage et al; J Neurooncology 2009 ChibbaroSurgNeurol 2008

  22. Mechanical Prophylaxis in sICH works! • 133/151 evaluated at day 10 after ICH • Endpoints: a/symptomatic DVT/PE • 14 asymptomatic DVT’s identified • 3 in ES only group • 11 in ES + IPC group • IPC combined with graded ES reduced the risk of asymptomatic DVT at day 10 following ICH by 71% compared with ES alone. Lacut et al; Neurology 2005 (VICTORIAh study)

  23. Anticoagulants in prevention of VTE in sICH • Meta-analysis of RCT’s of prophylactic use (within 6 days) of SQ • UFH • LMWH • Heparinoids • Endpoints: • A/symptomatic DVT • A/symptomatic PE • Death • A/symptomatic hematoma enlargement Paciaroni et al; J Thrombosis and Haemostasis 2011

  24. Anticoagulants in prevention of VTE in sICH • 4 studies included • 2 used UFH • 2 used LMWH • Results: • A/C resulted in sig reduction in: • PE • A/C resulted in NON-sig • Reduction in mortality • Reduction in DVT • Hematoma enlargement Paciaroni et al; J Thrombosis and Haemostasis 2011

  25. Other Studies… 97 patients with sICH were all given LMWH in the form of Enoxaparin or Dalteparin 2 patients developed moderate enlargement of hematoma No fatal PE’s Limitations: Non-randomized; no control group; limited sample size Kiphuth et al; Cerebrovasc Dis 2009

  26. Anticoagulants in prevention of VTE in traumatic ICH • 2 cohorts of 107, 129 pts each with tICH (1 served as a historic control) • Both groups tx with SCD’s • Following stable Head CT, 1 group underwent tx with either LMWH (Lovenox 30mg BID or SQUFH 5000 TID) • Group A (no tx): DVT rate was 5.6% • Group B (tx): DVT rate was 0% • No progression of ICH • NO sig difference in rate of PE (P = 0.179) with trend towards lower rate of PE in pts undergoing pharmacological prophylaxis Farooqui et al; J Neurosurg 2013

  27. Summary: Pharmacological DVT prophylaxis in the setting of ICH • In general, rates of DVT and PE are reduced with the use of pharmacological prophylaxis in the setting of sICH and tICH • There is probably no significant hematoma enlargement with the use of such prophylaxis • However, many studies show no significant correlation between DVT and PE; some show no significant reduction in rate of PE with pharm prophylaxis • The idea that mortality is reduced with the use of pharmacological DVT prophylaxis is yet to be proven

  28. Thank You

More Related